DOCSLIB.ORG

International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU ( 2 (51) International Patent Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61K 39/42 (2006.01) C07K 16/10 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, C07K 16/08 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 19/033 995 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (22) International Filing Date: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 24 May 2019 (24.05.2019) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available) . ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/676,045 24 May 2018 (24.05.2018) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: LANKENAU INSTITUTE FOR MEDICAL TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, RESEARCH [US/US]; 100 Lancaster Avenue, Wyn- KM, ML, MR, NE, SN, TD, TG). newood, PA 19096 (US). (72) Inventor: DESSAIN, Scott K.; 1370 Indian Creek Drive, Published: Wynnewood, PA 19096 (US). — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (74) Agent: BAK, Mary E. et al. ; Howson & Howson LLP, 350 claims and to be republished in the event of receipt of Sentry Parkway, Building 620, Suite 210, Blue Bell, PA amendments (Rule 48.2(h)) 19422 (US). — with sequence listing part of description (Rule 5.2(a)) (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (54) Title: COMPOSITIONS COMPRISING ANTIBODIES TO RABIES VIRUS AND THE USES THEREOF (57) Abstract: Anti-rabies antibodies e ito e-bindin fra ments and com osi¬ are er¬ COMPOSITIONS COMPRISING ANTIBODIES TO RABIES VIRUS AND THE USES THEREOF INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED IN ELECTRONIC FORM Applicant hereby incorporates by reference the Sequence Listing material filed in electronic form herewith. This file is labeled "MLHl05PCT_20l90523_ SequenceListing_ST25.txt", prepared May 24, 2019 and is 36,864 bytes in size. BACKGROUND OF THE INVENTION Rabies, being a major zoonotic disease, significantly impacts global public health. It is invariably fatal once clinical signs are apparent. The majority of human rabies deaths occur in developing countries. According to the CDC, more than 55,000 people, mostly in Africa and Asia, die from rabies every year - a rate of one person every ten minutes. India alone reports more than 50% of the global rabies deaths. Despite evidence that control of dog rabies through programs of animal vaccination and elimination of stray dogs can reduce the incidence of human rabies, exposure to rabid dogs is still the cause of over 90% of human exposures to rabies and of over 99% of human deaths worldwide. Because vaccines to prevent human rabies have been available for more than 100 years, most deaths from rabies occur in countries with inadequate public health resources and limited access to preventive treatment. These countries also have few diagnostic facilities and almost no rabies surveillance. The cost of these rabies prevention programs prohibits their full implementation in much of the developing world, and in even the most prosperous countries the cost of an effective dog rabies control program is a drain on public health resources. The estimated annual expenditure for rabies prevention in the United States is over US$300 million, most of which is spent on dog vaccinations. An annual turnover of approximately 25% in the dog population necessitates revaccination of millions of animals each year, and reintroduction of rabies through transport of infected animals from outside a controlled area is always a possibility should control programs lapse. Cell culture rabies vaccines have become widely available in developing countries. Currently, rabies vaccines made from inactivated cell cultures include human diploid cell vaccine (Imovax Rabies) and Purified Chick Embryo Cell Vaccine (RabAvert) and are well tolerated. Although it is a vaccine-preventable disease, effective rabies prevention in humans for post-exposure cases (i.e., category III bites) can require the combined administration of both rabies immunoglobulin (RIG) and vaccine. In still other instances, passive immunization with human anti-rabies immunoglobulin is valuable particularly in children and adults who have weakened immune systems or may not be good candidates for routine vaccinations for other reasons. It can be used with people who haven’t been vaccinated against a disease to which they’ve been exposed. For example, the passive rabies immunization (rabies immune globulin) is commonly used after a certain type of wild animal bites a child. SUMMARY OF THE INVENTION In one aspect, a recombinant, synthetic or monoclonal human antibody of an IgG class that binds to a rabies virus epitope, or a fragment of said antibody that binds a rabies virus epitope, is provided. The antibody or fragment comprises in one aspect, a heavy chain variable domain sequence that is an amino acid sequence selected from the group consisting of SEQ ID NO: 9, 11, 3, 5, 7, or 1 or an amino acid sequence at least 80% identical to SEQ ID NO: 9, 11, 3, 5, 7, or 1. In another aspect, the antibody or fragment comprises a light chain variable domain sequence that is an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 12, 4, 6, 8 or 2 or an amino acid sequence at least 80% identical to these sequences. In still another embodiment, truncations and/or modifications of these sequences SEQ ID NO: 1-12 are described. In still another aspect, the antibody or fragment comprises both heavy chain and light chain variable regions from among those SEQ ID Nos identified herein. In a further embodiment, the antibody comprises a heavy chain and light chain sequence of SEQ ID NOs: 9 and 10, referred to as antibody 8C5. In a further embodiment, the antibody comprises a heavy chain and light chain sequence of SEQ ID NOs: 11 and 12, referred to as antibody 10H5. In a further embodiment, the antibody comprises a heavy chain and light chain sequence of SEQ ID NOs: 3 and 4, referred to as antibody 4H3. In a further embodiment, the antibody comprises a heavy chain/light chain sequence of SEQ ID NOs: 5 and 6, referred to as antibody 7A2. In another embodiment, the antibody comprises a heavy chain and light chain sequence of SEQ ID NOs: 7 and 8, referred to as antibody 7E8. In a further embodiment, the antibody comprises a heavy chain and light chain sequence of SEQ ID NOs: 1 and 2, referred to as antibody 4C12. In another aspect, a pharmaceutical composition for the prevention or treatment of rabies infection is provided that comprises at least one antibody or epitope-binding fragment or modification thereof described herein and a pharmaceutically acceptable carrier. In another aspect, nucleic acid sequences encoding the antibody fragments, and constructs (e.g., vectors or plasmids) containing the coding sequences, as well as compositions containing the nucleic acid sequences, vectors, or plasmids are also provided. In another aspect, a method for preventing rabies infection in an uninfected subject comprises administering an effective amount of a single antibody or epitope binding fragment or modification thereof as described herein. In another aspect, a method for preventing rabies infection in an uninfected subject comprises administering an effective amount of a mixture of antibodies or fragments described herein. In another aspect, a method for preventing rabies infection in a subject suspected of having rabies infection comprises administering an effective amount of a single antibody or epitope binding fragment or modification thereof as described herein. In another aspect, a method for preventing rabies infection in a subject suspected of having rabies infection comprises administering an effective amount of a mixture of antibodies or fragments described herein. In another aspect, a method for treating a subject infected with rabies virus comprises administering an effective amount of a single antibody or epitope binding fragment or modification thereof. In another aspect, a method for treating a subject infected with rabies virus comprises administering an effective amount of a mixture of antibodies or fragments as described herein. Methods of generating the antibodies, using the nucleic acid sequences and formulating the pharmaceutical compositions are also provided. Other aspects and advantages of these methods and compositions are described further in the following detailed description. BRIEF DESCRIPTION OF THE FIGURES FIGs. 1A, 1B and 1C identify the heavy and light chain amino acid sequences of anti-rabies antibodies 4C12, 4H3, 7A2, 7E8, 8C5 and 10H5 with accompanying SEQ ID Nos and with the CDR sequences highlighted in each sequence. The symbols used in the figures are: HC = heavy chain; LLC = lambda light chain; KLC = kappa light chain; numbers in brackets denote the sequence length. FIGs. 2A, 2B, 2C and 2D provide the nucleotide sequences encoding the heavy and light chains of anti-rabies antibodies 4C12, 4H3, 7A2, 7E8, 8C5 and 10H5 with accompanying SEQ ID NOs and with the CDR-encoding sequences highlighted in each sequence.
Load more

Recommended publications
  • Fig. 1C Combination Therapy of Tumor Targeted ICOS Agonists with T-Cell Bispecific Molecules
    ( (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/30 (2006.01) A61P 35/00 (2006.01) kind of national protection av ailable) . AE, AG, AL, AM, C07K 16/28 (2006.01) A 6IK 39/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, C07K 16/40 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, PCT/EP20 18/086046 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 20 December 2018 (20. 12.2018) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available) . ARIPO (BW, GH, 17209444.3 2 1 December 2017 (21. 12.2017) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant (for all designated States except US): F. HOFF- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 124, 4070 Basel (CH).
    [Show full text]
  • Protein Conjugation with Triazolinediones: Switching from a General Tyrosine-Selective Labeling Method to a Highly Specific Tryptophan Bioconjugation Strategy Klaas W
    Protein Conjugation with Triazolinediones: Switching from a General Tyrosine-Selective Labeling Method to a Highly Specific Tryptophan Bioconjugation Strategy Klaas W. Decoene,† Kamil Unal,‡ An Staes⟠Ψ, Kris Gevaert⟠, Johan M. Winne,‡ Annemieke Madder†* † Organic and Biomimetic Chemistry Research group OBCR, Department of Organic and Macromolecular Chemistry, Faculty of Sciences, Ghent University, Krijgslaan 281 S4, 9000 Ghent, Belgium ‡ Organic Synthesis group, Department of Organic and Macromolecular Chemistry, Faculty of Sciences, Ghent University, Krijgslaan 281 S4, 9000 Ghent, Belgium ⟠ VIB Centre for Medical Biotechnology, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium & Department of Bio- molecular Medicine, Ghent University, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium Ψ VIB core facility , VIB Centre for Medical Biotechnology, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium ABSTRACT: Selective labeling of tyrosine residues in peptides and proteins can be achieved via a 'tyrosine-click' reaction with triazolinedione reagents (TAD). We have found that tryptophan residues are in fact often also labeled with this reagent. This off-target labeling is only observed at very low levels in protein bioconjugation but remains under the radar due to the low relative abundance of tryptophan compared to tyrosines in natural proteins, and because of the low availability and ac- cessibility of their nucleophilic positions at the solvent-exposed protein surface. Moreover, because TAD-Trp adducts are known to be readily thermoreversible, it can be challenging to detect these physiologically stable but thermally labile modi- fications using several MS/MS techniques. We have found that fully solvent-exposed tryptophan side chains are kinetically favored over tyrosines under almost all conditions, and this selectivity can even be further enhanced by modifying the pH of the aqueous buffer to effect selective Trp-labeling.
    [Show full text]
  • Affinity Chromatography (AC)
    Affinity Chromatography (AC) 1 Affinity Chromatography (AC) • Principles of AC • Main stages in Chromatography • How to prepare Affinity gel - Ligand Immobilization - Spacer arms – Coupling methods – Coupling tips • Types of AC • Elution Conditions • Binding equilibrium, competitive elution, kinetics • Industrial Examples: Protein A/G for Therapeutic proteins • Future Considerations 2 What is affinity chromatography? Affinity chromatography is a technique of liquid chromatography which separates molecules through biospecific interactions. The molecule to be purified is specifically and reversibly adsorbed to a specific ligand The ligand is immobilized to an insoluble support (“matrix”): resin, “chip”, Elisa plate, membrane, Western, IP (immuneprecipitation), etc Introduction of a “spacer arm” between the ligand and the matrix to improve binding Elution of the bound target molecule a) non specific or b) specific elution method 3 What is it used for? Monoclonal and polyclonal antibodies Fusion proteins Enzymes DNA-binding proteins . ANY protein where we have a binding partner!! 4 Designing and preparing an affinity gel Choosing the matrix Designing the ligand - Spacer arms Coupling methods 5 Ligand Immobilization Ligand + Activating agent + Matrix Activated Immobilised matrix ligand 6 Designing the ligand Essential ligand properties: interacts selectively and reversibly with the target Carries groups which can couple it to the matrix without losing its binding activity Available in a pure form 7 Steric considerations & spacer arms Small ligand (<1,000) Risk of steric interference with binding between matrix and target molecule Often need spacer arm but watch out for Spacer arm adsorption to the spacer! 8 Design of spacer arms Alkyl chain Real risk of unspecific interactions between H H spacer and target molecule O O Hydrophilic chain Risk of unspecific interactions greatly O H reduced No coupling reaction will use 100% of the available binding sites.
    [Show full text]
  • EURL ECVAM Recommendation on Non-Animal-Derived Antibodies
    EURL ECVAM Recommendation on Non-Animal-Derived Antibodies EUR 30185 EN Joint Research Centre This publication is a Science for Policy report by the Joint Research Centre (JRC), the European Commission’s science and knowledge service. It aims to provide evidence-based scientific support to the European policymaking process. The scientific output expressed does not imply a policy position of the European Commission. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this publication. For information on the methodology and quality underlying the data used in this publication for which the source is neither Eurostat nor other Commission services, users should contact the referenced source. EURL ECVAM Recommendations The aim of a EURL ECVAM Recommendation is to provide the views of the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) on the scientific validity of alternative test methods, to advise on possible applications and implications, and to suggest follow-up activities to promote alternative methods and address knowledge gaps. During the development of its Recommendation, EURL ECVAM typically mandates the EURL ECVAM Scientific Advisory Committee (ESAC) to carry out an independent scientific peer review which is communicated as an ESAC Opinion and Working Group report. In addition, EURL ECVAM consults with other Commission services, EURL ECVAM’s advisory body for Preliminary Assessment of Regulatory Relevance (PARERE), the EURL ECVAM Stakeholder Forum (ESTAF) and with partner organisations of the International Collaboration on Alternative Test Methods (ICATM). Contact information European Commission, Joint Research Centre (JRC), Chemical Safety and Alternative Methods Unit (F3) Address: via E.
    [Show full text]
  • Generation of Novel Intracellular Binding Reagents Based on the Human Γb-Crystallin Scaffold
    Generation of novel intracellular binding reagents based on the human γB-crystallin scaffold Dissertation zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) vorgelegt der Naturwissenschaftlichen Fakultät I-Biowissenschaften der Martin-Luther-Universität Halle-Wittenberg Institut für Biochemie und Biotechnologie von Ewa Mirecka geboren am 17. Dezember 1976 in Gdynia, Polen Table of contents Table of contents 1. INTRODUCTION.........................................................................................................1 1.1 Monoclonal antibodies as a biomolecular scaffold..........................................................1 1.2 Binding molecules derived from non-immunoglobulin scaffolds.....................................3 1.2.1 Alternative protein scaffolds – general considerations............................................................ 3 1.2.2 Application of alternative binding molecules ........................................................................... 6 1.3 Affilin – novel binding molecules based on the human γB-crystallin scaffold................... 6 1.3.1 Human γB-crystallin as a molecular scaffold........................................................................... 6 1.3.2 Generation of a human γB-crystallin library and selection of first-generation Affilin molecules ................................................................................................................................ 8 1.4 Selection of binding proteins by phage display ...................................................................
    [Show full text]
  • Selection of an Artificial Binding Protein Against the Ectodomain of PTH1R
    Selection of an artificial binding protein against the ectodomain of PTH1R Dissertation Zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) vorgelegt bei der Naturwissenschaftlichen Fakultät I Biowissenschaften der Martin-Luther-Universität Halle-Wittenberg von Qi Zhang geboren am 21.09.1983 in Shaanxi, China Gutachter /in 1. PD. Dr. Hauke Lilie 2. Prof. Dr. Jochen Balbach 3. Prof. Dr. Annette G. Beck-Sickinger Verteidigungsdatum: 14.03.2013 Zusammenfassung In den vergangenen Jahrzehnten fanden mehr als 30 Immunglobuline (IgGs) und deren Derivate Anwendung in der klinischen Praxis. Trotz des großen Erfolgs solcher Antikörper-basierter Medikamente traten auch einige Limitationen auf. Gerüstproteine stellen eine Alternative zu herkömmlichen Antikörpern dar. Sie weisen meist eine hohe thermodynamische Stabilität auf und bestehen aus einer einzelnen Polypeptidkette ohne Disulfidbrücken. Universelle Bindestellen können wie beim humanen Fibronectin III und bei Anticalinen in flexiblen Loop-Regionen erzeugt werden oder auf rigiden Sekundärstrukturelementen, wie im Fall der Affibodies, DARPine und Affiline. In der vorliegenden Arbeit wurde eine Protein-Bibliothek auf Basis des humanen γB-Kristallins, unter Randomisierung von 8 oberflächenexponierten Aminosäuren auf einem β-Faltblatt der N-terminalen Domäne des Proteins, hergestellt. Ein kürzlich entwickeltes Screening-System, das T7-basierte Phagen-Display, wurde zur Durchmusterung der Bibliothek auf potentielle Binder angewandt. Dabei erfolgt die Assemblierung der Protein-präsentierenden Phagenpartikel ohne einen Transportschritt über die Zellmembran hinweg bereits im Cytoplasma von E. coli. G-Protein gekoppelte Rezeptoren (GPCRs) bilden nur schwerlich für Strukturuntersuchungen geeignete, geordnete Kristallstrukturen aus. Kleine, gut lösliche Bindeproteine könnten sie in einer bestimmten Konformation fixieren und so den Anteil an hydrophilen Resten auf der Proteinoberfläche erhöhen.
    [Show full text]
  • The Organizing Committee Gratefully Acknowledges the Symposium
    2nd Symposium on Higher Order Structure of Protein Therapeutics February 11 – 13, 2013 Hyatt Regency Baltimore on the Inner Harbor Baltimore, Maryland USA Organized by 1 Table of Contents Program Partners ..........................................................................................................3 Exhibitor and Media Partners.......................................................................................4 Acknowledgements ......................................................................................................5 Student Travel Grants ..................................................................................................6 Scientific Final Program Summary ..............................................................................7 Plenary and Session Abstracts .....................................................................................16 Technical Seminar I (Monday, February 11) Abstract ................................................55 Technical Seminar II (Tuesday, February 12) Abstract...............................................56 Technical Seminar III (Tuesday, February 12) Abstract .............................................57 Poster Abstracts ............................................................................................................58 2 The Organizing Committee gratefully acknowledges the Corporate Program Partners for their generous support of the 2nd Symposium on Higher Order Structure of Protein Therapeutics Sustaining Gold Program Partners AbbVie Inc.
    [Show full text]
  • Understanding Ubiquitin Recognition and Generating Affinity Reagents
    Ubiquitin Engineering: Understanding Ubiquitin Recognition and Generating Affinity Reagents by Isabel Leung A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Molecular Genetics University of Toronto © Copyright by Isabel Leung 2017 Abstract Ubiquitin Engineering: Understanding Ubiquitin Recognition and Generating Affinity Reagents Isabel Leung Doctor of Philosophy Department of Molecular Genetics University of Toronto 2016 Protein-protein interactions are necessary for virtually all biological processes. There have been tremendous efforts to document the diversity of molecular recognition, and to understand how molecular recognition occurs. The understanding of molecular interaction has also served as the foundation for designing novel protein interactions for use in therapeutics, diagnostics and basic sciences. An attractive system for studying protein-protein interactions is the ubiquitin (Ub) system. Ub is a protein modifier that is combinatorially ligated onto substrate proteins to influence substrate turnover and function. Ub uses a common surface to interact with more than 1000 proteins and plays pivotal roles in cell physiology. Despite the substantial structural information on Ub mediated interactions, there is no clear understanding of how individual Ub residues contribute to Ub’s broad scope of interactions. To address this question, I used affinity enhanced Ub variants (Ubvs) as proxies of native Ub in saturation scanning. Using saturation scanning, I studied the interactions between Ubvs and two Ub specific proteases (USP), USP2 and USP21, and elucidated a common functional epitope that is critical for USP recognition. The functional epitope recognizes USP residues that are conserved among the human USP family, suggesting it may make functional contributions in many other USP interactions.
    [Show full text]
  • WO 2018/218207 Al 29 November 2018 (29.11.2018) W !P O PCT
    (t) include a VL chain of SEQ ID NO: 24 and a VH chain of SEQ ID NO: 25; (u) include a VL chain of SEQ ID NO: 84 and a VH chain of SEQ ID NO: 83; (v) include a VL chain of SEQ ID NO: 154 and a VH chain of SEQ ID NO: 155; (w) include CDRs including SEQ ID NO: 85; SEQ ID NO: 86; SEQ ID NO: 87; SEQ ID NO: 88; SEQ ID NO: 89; and SEQ ID NO: 90; (x) include CDRs including SEQ ID NO: 130; SEQ ID NO: 13 1; SEQ ID NO: 132; SEQ ID NO: 133; SEQ ID NO: 134; and SEQ ID NO: 135; (y) include CDRs including SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110 , and SEQ ID NO: 111; (z) include CDRs including SEQ ID NO: 112 , SEQ ID NO: 113 , SEQ ID NO: 114 , SEQ ID NO: 115 , SEQ ID NO: 116 , and SEQ ID NO: 117 ; (aa) include CDRs including SEQ ID NO: 118 , SEQ ID NO: 119 , SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, and SEQ ID NO: 123; (bb) include CDRs including SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, and SEQ ID NO: 129; (cc) include CDRs including SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, and SEQ ID NO: 14 1; (dd) include CDRs including SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, and SEQ ID NO: 147 (ee) include CDRs including SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, and SEQ ID NO: 99; (ff) include CDRs including SEQ ID NO: 100, SEQ ID NO: 10 1, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, and SEQ ID NO: 105; (gg) include CDRs including SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 15 1, SEQ ID NO: 152, and SEQ ID NO: 153; (hh) includes a humanized sequence of an antibody disclosed herein; and/or (ii) binds to endogenous human CD33 with a KD of less than 10 nM.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0112915 A1 Bardroff Et Al
    US 201401 12915A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0112915 A1 Bardroff et al. (43) Pub. Date: Apr. 24, 2014 (54) IL-18 BINDING MOLECULES Publication Classification (71) Applicants: Michael Otto Bardroff, Loerrach (DE); (51) Int. Cl. Barbara Brannetti, Basel (CH); Emma C07K 6/24 (2006.01) Michelle Campbell, Surrey (GB); Beate GOIN33/68 (2006.01) Diefenbach-Streiber, Windach (DE): (52) U.S. Cl. Adina Eberth, Munich (DE); Christian CPC .......... C07K 16/244 (2013.01); G0IN33/6854 Carsten Silvester Kunz, Muenchen (2013.01) (DE); Sylwia Marshall, Epsom (GB); USPC ... 424/133.1; 424/139.1; 435/7.92; 435/69.6; Jean-Michel Rene Rondeau, Rixheim 435/331; 435/320.1; 530/387.3; 530/387.9; (FR); Jean-Marc Alfred Schlaeppi, 536/2353 Allschwil (CH); Gino Anselmus Van Heeke, Upper Beeding (GB) (57) ABSTRACT (72) Inventors: Michael Otto Bardroff, Loerrach (DE); Barbara Brannetti, Basel (CH); Emma Michelle Campbell, Surrey (GB); Beate IL-18 participates in both innate and acquired immunity. The Diefenbach-Streiber, Windach (DE): bioactivity of IL-18 is negatively regulated by the IL-18 bind Adina Eberth, Munich (DE); Christian ing protein (IL18BP), a naturally occurring and highly spe Carsten Silvester Kunz, Muenchen cific inhibitor. This soluble proteinforms a complex with free (DE); Sylwia Marshall, Epsom (GB); IL-18 preventing its interaction with the IL-18 receptor, thus Jean-Michel Rene Rondeau, Rixheim neutralizing and inhibiting its biological activity. The present (FR); Jean-Marc Alfred Schlaeppi, invention discloses binding molecules, in particular antibod Allschwil (CH); Gino Anselmus Van ies or fragments thereof, which bind IL-18 and do not bind Heeke, Upper Beeding (GB) IL-18 bound to IL-18BP (IL-18/IL-18BP complex).
    [Show full text]
  • THE ESSENTIAL PROTEIN ENGINEERING SUMMIT May 1-5
    FINAL DAYS 13TH ANNUAL TO REGISTER COVER CONFERENCE-AT-A-GLANCE SPONSORS May 1-5, 2017 • Seaport World Trade Center SHORT COURSES TRAINING SEMINARS ENGINEERING THE ESSENTIAL PROTEIN ENGINEERING SUMMIT STREAM ONCOLOGY STREAM PLENARY KEYNOTE: EVENT FEATURES: IMMUNOTHERAPY STREAM Sir Gregory Winter, Ph.D., NEW Young Scientist Keynote Presentation FRS, Master, Trinity College and 2,200+ Global 19 Short Courses EXPRESSION STREAM Co-Founder and Director, Bicycle Attendees 325+ Influential Therapeutics 22 Conference Speakers ANALYTICAL Tracks STREAM 100+ Exhibiting 6 Training Seminars Companies IMMUNOGENICITY & BIOASSAY STREAM BIOCONJUGATES STREAM THERAPEUTICS STREAM SPONSOR & EXHIBITOR INFO HOTEL & TRAVEL REGISTRATION INFORMATION Register Online! PEGSummit.com Premier Sponsors A Division of Cambridge Innovation Institute PEGSummit.com | 1 FINAL DAYS TO REGISTER CONFERENCE AT A GLANCE COVER CONFERENCE-AT-A-GLANCE SPONSORS SHORT COURSES SUNDAY MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY TRAINING SEMINARS April 29 May 1 May 2 May 3 May 4 May 5 ENGINEERING Engineering Display of Antibodies Engineering Antibodies STREAM Bispecific Antibodies ONCOLOGY Antibodies for Advancing Bispecific Antibodies ADCs II: STREAM Cancer Therapy to the Clinic for Oncology Advancing Toward the Clinic IMMUNOTHERAPY Preventing Toxicity Adoptive Agonist STREAM in Immunotherapy T-Cell Therapy Immunotherapy Targets Optimizing Protein Expression EXPRESSION Difficult to Express Proteins STREAM Protein Expression System Engineering ANALYTICAL Characterization Biophysical Analysis
    [Show full text]
  • WO 2019/046815 Al 07 March 2019 (07.03.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/046815 Al 07 March 2019 (07.03.2019) W 1P O PCT (51) International Patent Classification: OSTERTAG, Eric [US/US]; 4242 Campus Point Court, C12N 15/90 (2006.01) Suite 700, San Diego, California 82121 (US). RICHTER, Maximilian [US/US]; 473 1Kansas Street, San Diego, Cal¬ (21) International Application Number: ifornia 921 16 (US). CRANERT, Stacey Ann [US/US]; PCT/US20 18/049257 7693 Palmilla Dr. Apt. 2103, San Diego, California 92122 (22) International Filing Date: (US). 31 August 2018 (3 1.08.2018) (74) Agent: MILLER, Katherine J. et al.; COOLEY LLP, (25) Filing Language: English 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/552,861 31 August 2017 (3 1.08.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/558,286 13 September 2017 (13.09.2017) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/608,546 20 December 2017 (20. 12.2017) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (71) Applicant: POSEIDA THERAPEUTICS, INC. HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, [US/US]; 4242 Campus Point Court, Suite 700, San Diego, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, California 92121 (US).
    [Show full text]